Shantha Biotechnics is an Indian biotechnology company based in Hyderabad. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group. Wikipedia.
Bhattacharya S.K.,Indian National Institute of Cholera and Enteric Diseases |
Bhattacharya S.K.,Indian Council of Medical Research |
Sur D.,Indian National Institute of Cholera and Enteric Diseases |
Ali M.,Korean International Vaccine Institute |
And 19 more authors.
The Lancet Infectious Diseases | Year: 2013
Background: Efficacy and safety of a two-dose regimen of bivalent killed whole-cell oral cholera vaccine (Shantha Biotechnics, Hyderabad, India) to 3 years is established, but long-term efficacy is not. We aimed to assess protective efficacy up to 5 years in a slum area of Kolkata, India. Methods: In our double-blind, cluster-randomised, placebo-controlled trial, we assessed incidence of cholera in non-pregnant individuals older than 1 year residing in 3933 dwellings (clusters) in Kolkata, India. We randomly allocated participants, by dwelling, to receive two oral doses of modified killed bivalent whole-cell cholera vaccine or heat-killed Escherichia coli K12 placebo, 14 days apart. Randomisation was done by use of a computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for patients to seek treatment in a health-care facility. We identified culture-confirmed cholera cases among participants seeking treatment for diarrhoea at a study clinic or government hospital between 14 days and 1825 days after receipt of the second dose. We assessed vaccine protection in a per-protocol population of participants who had completely ingested two doses of assigned study treatment. Findings: 69 of 31932 recipients of vaccine and 219 of 34968 recipients of placebo developed cholera during 5 year follow-up (incidence 2·2 per 1000 in the vaccine group and 6·3 per 1000 in the placebo group). Cumulative protective efficacy of the vaccine at 5 years was 65% (95% CI 52-74; p<0·0001), and point estimates by year of follow-up suggested no evidence of decline in protective efficacy. Interpretation: Sustained protection for 5 years at the level we reported has not been noted previously with other oral cholera vaccines. Established long-term efficacy of this vaccine could assist policy makers formulate rational vaccination strategies to reduce overall cholera burden in endemic settings. Funding: Bill & Melinda Gates Foundation and the governments of South Korea and Sweden. © 2013 Elsevier Ltd.
Mangal S.,Dr Hari Singh Gour University |
Mangal S.,Shantha Biotechnics |
Pawar D.,Dr Hari Singh Gour University |
Garg N.K.,Dr Hari Singh Gour University |
And 4 more authors.
Vaccine | Year: 2011
Tri-methyl chitosan synthesis accompanies polymer chain scission, which may affect the carrier and adjuvant properties of the polymer. The main objective of this study was to synthesize the tri-methylated chitosan using mild (TMC-M) and conventional (TMC) method and compare their efficacy as nasal vaccine delivery vehicle. During in vitro studies TMC-M nanoparticles showed the lowest nasal clearance rate when compared with chitosan (CS) and TMC nanoparticles. The immunogenicity of nanoparticles based delivery system(s) was assessed by measuring anti-HBsAg antibody titer in mice serum and secretions after intranasal administration. The alum based HBsAg vaccine injected subcutaneously was used as positive control. Results indicated that alum based HBsAg induced strong humoral but negligible mucosal immunity. However, TMC-M nanoparticles induced stronger immune response at both of the fronts as compared to generated by CS or TMC nanoparticles. Present study demonstrates that TMC-M can be a better carrier adjuvant for nasal subunit vaccines. © 2011 Elsevier Ltd.
Pawar D.,Jawaharlal Nehru University |
Pawar D.,Shantha Biotechnics |
Mangal S.,Shantha Biotechnics |
Goswami R.,Shantha Biotechnics |
Jaganathan K.S.,Shantha Biotechnics
European Journal of Pharmaceutics and Biopharmaceutics | Year: 2013
In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a mucoadhesive coating material in nasal vaccine delivery was investigated. The Hepatitis B surface Antigen (HBsAg) encapsulated PLGA, chitosan coated PLGA (C-PLGA), and Glycol chitosan coated PLGA (GC-PLGA) nanoparticles (NPs) were prepared. The formulations were characterized for particle size, shape, surface charge, and entrapment efficiency. The mucoadhesive ability of coated and non-coated NPs was determined using in vitro mucoadhesion and nasal clearance test. In addition, the systemic uptake and bio-distribution were also evaluated to understand the fate of NPs following nasal delivery. The immuno-adjuvant ability of various formulations was compared by measuring specific antibody titer in serum and secretory. The results indicated that PLGA NPs exhibit negative surface charge, whereas C-PLGA and GC-PLGA NPs exhibited positive surface charge. The GC-PLGA NPs demonstrated lower clearance and better local and systemic uptake compared to chitosan coated and uncoated PLGA NPs. In vivo immunogenicity studies indicated that GC-PLGA NPs could induce significantly higher systemic and mucosal immune response compared to PLGA and C-PLGA NPs. In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation.
Jagu S.,Johns Hopkins University |
Kwak K.,Johns Hopkins University |
Karanam B.,Johns Hopkins University |
Huh W.K.,University of Alabama at Birmingham |
And 3 more authors.
PLoS ONE | Year: 2013
We sought to define the protective epitopes within the amino terminus of human papillomavirus (HPV) type 16 minor capsid protein L2. Passive transfer of mice with rabbit antisera to HPV16 L2 peptides 17-36, 32-51 and 65-81 provided significant protection against vaginal HPV16 challenge, whereas antisera to 47-66, 108-120 or 373-392 did not. Vaccination with L1 virus-like particles induces a high titer, but generally type-restricted neutralizing antibody response. Conversely, vaccination with L2 11-88, especially multimers thereof, induces antibodies that neutralize a broad range of papillomavirus types, albeit at lower titers than for L1 VLP. With the intent of enhancing the immunogenicity and the breadth of protection by focusing the immune response to the key protective epitopes, we designed L2 fusion proteins consisting of residues ~11-88 of eight divergent mucosal HPV types 6, 16, 18, 31, 39, 51, 56, 73 (11-88×8) or residues ~13-47 of fifteen HPV types (13-47×15). The 11-88×8 was significantly more immunogenic than 13-47×15 in Balb/c mice regardless of the adjuvant used, suggesting the value of including the 65-81 protective epitope in the vaccine. Since the L2 47-66 peptide antiserum failed to elicit significant protection, we generated an 11-88×8 construct deleted for this region in each subunit (11-88×8Δ). Mice were vaccinated with 11-88×8 and 11-88×8Δ to determine if deletion of this non-protective epitope enhanced the neutralizing antibody response. However, 11-88×8Δ was significantly less immunogenic than 11-88×8, and even the addition of a known T helper epitope, PADRE, to the construct (11-88×8ΔPADRE) failed to recover the immunogenicity of 11-88×8 in C57BL/6 mice, suggesting that while L2 47-66 is not a critical protective or T helper epitope, it nevertheless contributes to the immunogenicity of the L2 11-88×8 multimer vaccine. © 2013 Jagu et al.
Shantha Biotechnics | Date: 2014-05-15
The invention describes a method of purifying polysaccharide protein conjugates using mixed mode chromatography. The method involves contacting a crude polysaccharide protein conjugate with a mixed mode resin comprising an inert porous shell and an activated core under conditions of low conductivity that allow binding of the contaminants and collecting the unbound polysaccharide protein conjugate in a flowthrough.
News Article | November 9, 2016
The report provides comprehensive information on the therapeutics under development for Rotavirus Infections ,complete with analysis by stage of development,drug target,mechanism of action (MoA),route of administration (RoA) and molecule type. The report also coversthe descriptive pharmacological action of the therapeutics,its complete research and development history and latest news and press releases. Additionally,the report provides an overview of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios,enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Rotavirus Infections - Pipeline Review,H2 2016 addition with 26 market data tables and 13 figures, spread across 62 pages is available at http://www.rnrmarketresearch.com/rotavirus-infections-pipeline-review-h2-2016-market-report.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases,company/university websites,clinical trial registries,conferences,SEC filings,investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally,various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Beijing Minhai Biotechnology Co., Ltd,Bharat Biotech International Limited,Biological E. Limited,Curevac AG ,Medicago Inc. ,MSD Wellcome Trust Hilleman Laboratories Pvt Ltd,Nanotherapeutics, Inc.,Serum Institute of India Limited,Shantha Biotechnics Limited,Sinovac Biotech Ltd.,Takeda Pharmaceutical Company Limited,Wuhan Institute of Biological Products Co., Ltd. Inquire before buying http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=748014(This is a premium report price at US$2000 for a single user PDF license).
News Article | March 12, 2015
US-headquartered DiabetOmics Inc, a growth-stage medical diagnostics company with India operations, has raised its Series C round of funding worth $4 million from Ventureast to drive manufacturing and commercialisation in India, as per a company release. It has also raised an additional $1 million from KI Varaprasad Reddy, the founder of Shantha Biotechnics, who sold his company to Sanofi a few years ago. He will take over the post of chairman at DiabetOmics and will head the India unit once it is set up. DiabetOmics has developed a patented non-invasive, saliva-based glucose monitoring test for diabetes patients and an early detection test for gestational diabetes (in pregnant women) and pre-eclampsia (high blood pressure in pregnant women). The firm seeks to disrupt the market by doing away with the conventional diabetes monitoring process which involves a prick to get a small blood sample. This dissuades those suffering from diabetes and potential patients from testing their sample. The money raised will be invested to advance product development, obtain regulatory approvals in Europe, the US and in emerging markets and to set up a manufacturing facility in India and begin commercialisation. It plans to obtain CE Mark in 2015 and start commercialisation in India and several other countries in early 2016. Though it has not finalised a location for its manufacturing facility yet, it is evaluating options in Andhra Pradesh and Telangana, the newly carved state out of the south-eastern state of Andhra Pradesh. Srinivasa Nagalla, MD, president and CEO of DiabetOmics, said, “Lack of patient compliance with regular glucose monitoring is the primary cause of diabetes-related complications. We are looking to grow our presence in India to access Indian and SE-Asian markets.” Nagalla was previously founder and CEO of ProteoGenix, Inc., an innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. in 2010. Before founding ProteoGenix, he was associate professor of pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums of biotechnology, genomics and proteomics. He has over 20 years of broad multi-disciplinary experience in clinical medicine, biotechnology, and commercialisation. Nagalla received his MD from the All-India Institute of Medical Sciences, New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University. Talking about the investment, Venkatadri Bobba, general partner of Ventureast, said, “An important focus area for us has been investing in companies fostering cutting-edge and breakthrough innovations in healthcare. We believe that DiabetOmics’ device is a game-changer and will definitely be successful in India.” This is DiabetOmics third round of funding. It has previously raised $15 million from Rogue Venture Partners, Dudley Foundation and government grants. Ventureast is a sector agnostic multi-stage VC firm with a special focus on healthcare. Ventureast’s Life Fund focuses on investments in cleantech, food & agriculture and healthcare sectors. It has previously made cross-border deals in drug discovery, medical devices, diagnostics, biotechnology and healthcare delivery. This is Ventureast’s third investment in tech healthcare space. Previously, it had invested in OneBreath, a startup that develops portable and rechargeable ventilators, and SmartRx that helps communication between doctor and patients after they are discharged.
News Article | January 13, 2010
Deal activity however picked up in second half of year During 2009, Indian companies were involved in a total of 356 M&A deals, down 34% from 2008, according to a study by Venture Intelligence (http://www.ventureintelligence.in), a research service focused on Private Equity and M&A transaction activity in India. These figures were lower than that for 2008, which witnessed a total of 543 M&A deals (including 265 deals with an announced value of $26.4 billion). However, M&A activity in the second half of 2009 which witnessed 204 deals, was higher compared to H1 ’09 which had witnessed a total of 152 M&A deals. In the largest M&A deal by announced value, UltraTech Cement merged Samruddhi Cement with itself to form India’s largest cement company. This was followed by ONGC Videsh acquiring UK-listed Imperial Energy, which has oil assets in Russia, for $1.9 billion and Sanofi-Aventis’ acquisition of Hyderabad based Shantha Biotechnics for $625 million. Over 56% of the deals in 2009 were domestic acquisitions, as against the 43% in 2008. Indian companies cut down on their global acquisitions drastically executing just 85 outbound transactions in 2009 as compared to the 230 in the previous year. The US was the most preferred destination for Indian companies which acquired 22 American companies in 2009. The US was followed by the UK and Australia (with 9 deals each). The acquirers in 28 of the 70 inbound deals during 2009 were US-based companies, followed by German firms with ten deals and French firms with eight deals. The IT & ITES and Manufacturing industries accounted for most number of acquisitions during 2009 contributing 22% and 18% respectively. Healthcare, Energy and BFSI were the next most active industries for M&A activity. Venture Intelligence, a division of Chennai-based TSJ Media Pvt. Ltd., is the leading source of information on private equity and M&A transactions in India. For more information, please visit http://www.ventureintelligence.in
News Article | July 28, 2009
Tata Sons Exec Forms Advisory - Alan Rosling, the former executive director at Tata Sons, the group holding firm, has formed an advisory firm called Griffin Growth Partners. The firm would help MNCs develop business strategies for India, and will be based out of Mumbai and Hong Kong. Rosling played a key role in Tata's overseas expansion and acquisitions of Jaguar & Land Rover and steel manufacturer Corus. (WSJ) Shantha Founder may Sell Stake - Vara Prasad Reddy, the founder of Shantha Biotechnics who holds a 13.4% stake in firm, may sell his stake to the new owners. Sanofi Pasteur, a unit of French drug major Sanofi-Aventis, agreed to acquire Shantha yesterday at a valuaion of Euro 550 million. Sanofi has approached Reddy asking him to divest his full stake in Shantha. (Business Standard) Adani Power Becomes First To Rope in Anchor Investors - Adani Power initial public offer (IPO) has roped in six anchor investors , who have picked up the entire portion reserved under the scheme for Rs 502 crore at Rs 95 per share. These investors are T Rowe Price, AIC, Ecofin, TPG (through CLSA), Legg Mason and Sundaram MF. (BS) Intelligroup Looks For Acquisitions - Intelligroup Inc, a IT services provider, is pursuing acquisitions in the US and India, which have the right set of competencies in the business intelligence (BI), infrastructure management and testing space. The firm has earmarked $18 million for the buyouts. Intelligroup is an IT consulting, application management, support and implementation firm with its global delivery centres in Hyderabad and Bangalore. (BS) Lesha Energy Acquires Gorlas - Ahmedabad-based Lesha Energy Resources Limited (LERL) has gained access to oil and gas fields in Cambay Basin through acquisition of Hyderabad-based Gorlas Oil and Gas Pvt. Ltd. Gorlas is a 100% holding company of Heramec Ltd. for Rs 15.43 crore. Bahamas-based Heramec Ltd. has 30% participating interest in oil & gas fields of Cambay basin. (BS) Subhiksha CDR Terms Get Tougher - Troubled retailer Subhiksha’s bankers are looking to appoint an advisory board to keep a close tab on the company’s operations and a chief financial officer (CFO) to manage the finances. These terms will come as part of a corporate debt restructuring (CDR) package for Subhiksha. (BS) SingTel May Buy More Stake in Bharti Airtel - Singapore Telecommunications may buy more shares in Bharti Airtel from MTN shareholders in order to maintain its equity stake in the Indian telco at a minimum level of 26%. Singtel has informed banks including DBS, in addition to its advisor Goldman Sachs, to raise funds to finance such an acquisition of shares. If Bharti-MTN transaction goes through, it could reduce SingTel’s stake from 30% to 19%. (Economic Times)